Horizon Discovery and Mirna Therapeutics to Test Activities of Tumor Suppressor MicroRNAs

Horizon’s X-MANTM human cell lines will be used to define the effects of common mutations in cancer patients on the efficacy of Mirna’s miRNA mimics.

04-Nov-2010 - United Kingdom

Horizon Discovery and Mirna Therapeutics announced that they have entered into a collaboration agreement to test the impact of Mirna’s proprietary miRNA mimics on a panel of Horizon’s patient-relevant human isogenic cancer cell models.

One of the challenges that cancer researchers face in developing cancer therapeutics is that of predicting which patient sub-groups will respond to future drug treatments. Horizon’s novel, genetically-defined X-MANTM human cell lines (or “patients-in-a-test-tube”) will be used to test the effects of common mutations in cancer patients on the efficacy of Mirna’s miRNA mimics.

This project is funded in part by a Cancer Prevention and Research Institute of Texas (CPRIT) Commercialization grant.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances